[Pleural Well-differentiated Papillary Mesothelial Tumor Presenting with Recurrent Pneumothorax and Pleural Effusion: A Case Report] [0.03%]
反复气胸和血胸的良性间皮肿瘤一例报告
Zhe Li,Fanyi Kong,Bo Yang et al.
Zhe Li et al.
Well-differentiated papillary mesothelial tumor (WDPMT) is a rare neoplasm characterized by a distinct papillary architecture, bland cytological features, and a propensity for superficial spread without stromal invasion. We herein report th...
[Surgical Management of Lung Cancer in Patients with Interstitial Lung Disease] [0.03%]
间质性肺疾病患者的肺癌外科治疗
Yang Liu,Chuan Huang
Yang Liu
Interstitial lung disease (ILD) is characterized by varying degrees of inflammation and fibrosis of the pulmonary interstitium, posing a significant threat to human health. Patients with ILD have a significantly higher risk of developing lu...
[Current Status of Multidisciplinary Team Consultation for Lung Cancer and Prospects under the Empowerment of Medical Large Models] [0.03%]
[当前肺癌多学科团队会诊现状及医学大模型赋能力下的前景展望]
Yingxin Fu,Li Shan,Tingting Yu
Yingxin Fu
Lung cancer ranks among malignant neoplasms with the highest incidence and mortality, and its diagnosis and treatment are complicated, requiring multidisciplinary participation. Multidisciplinary team (MDT) consultation is the core model fo...
[Radiotherapy for SMARCA4-deficient Pulmonary Neoplasms: Efficacy and Related Parameter Analysis] [0.03%]
[S MARCA4缺陷型肺部肿瘤的放疗疗效及影响因素分析]
Yu Gu,Ruxi Gao,Xingwen Fan et al.
Yu Gu et al.
Background: SMARCA4-deficient pulmonary neoplasms have emerged as a major focus of lung cancer research in recent years. This subtype is characterized by aggressive behavior and poor prognosis. However, radiotherapy-relat...
[Clinicopathological Characteristics of ROS1-positive Non-small Cell Lung Cancer Based on Next-generation Sequencing] [0.03%]
基于下一代测序的ROS1阳性非小细胞肺癌的临床病理特征分析
Lina Gao,Li Sun,Weihua Li et al.
Lina Gao et al.
Background: C-ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) gene fusion-positive non-small cell lung cancer (NSCLC) is a high-risk subtype of lung cancer, and the accurate identification of this specific subtype is...
[Expression of S100P in Lung Adenocarcinoma and Its Clinical Significance] [0.03%]
肺腺癌中S100P的表达及其临床意义
Ziyi Ding,Donghui Zhang,Nanyang Li et al.
Ziyi Ding et al.
Background: Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer (NSCLC). Due to the lack of obvious symptoms and signs in the early stages, most patients are already in the mid...
[Chinese Expert Consensus on Diagnosis and Treatment of Non-small Cell Lung Cancer with MET Abnormality (2026 Version)] [0.03%]
中国非小细胞肺癌MET异常诊断治疗专家共识(2026版)
Jun Chen,Baohui Han,Yi Hu et al.
Jun Chen et al.
The mesenchymal-epithelial transition factor (MET) gene, located on human chromosome 7, exerts critical regulatory roles in cellular processes including proliferation, migration, invasion, and angiogenesis. As a key driver gene in non-small...
[Expert Consensus on Precision Management of Pulmonary Nodules (2026 Version)] [0.03%]
肺结节精准管理专家共识(2026版)
Juan Zhou,Yudong Zhang,Qinghua Zhou et al.
Juan Zhou et al.
With the wide application of low-dose spiral computed tomography and the advancement of imaging technology, the detection rate of pulmonary nodules has significantly increased. However, the traditional "one-size-fits-all" management strateg...
[A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment] [0.03%]
奥希替尼治疗后EGFR突变肺腺癌伴二次小细胞肺癌转化及ALK融合一例报告
Liyan Liao,Xiaohong Li
Liyan Liao
Epidermal growth factor receptor (EGFR) gene mutations are the most common driver mutations in non-small cell lung cancer (NSCLC). This article reports a case of a patient with EGFR-sensitive mutant lung adenocarcinoma who developed seconda...
[Potential Mechanisms and Research Advances of HDAC1 in Lung Cancer] [0.03%]
组蛋白去乙酰化酶1在肺癌中的潜在机制及研究进展
Mingzhu Liu,Chuanlin Wang,Jin Hu et al.
Mingzhu Liu et al.
Lung cancer is the malignant tumor with the highest incidence and mortality rate worldwide. The current treatment methods have limited efficacy, and the prognosis of patients is poor. There is an urgent need to explore new therapeutic targe...